Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: A descriptive study on the GETAID cohort

Journal of Crohn's and Colitis

Volumn 10, Issue 10, 2016, Pages 1179-1185

  Abitbol, Yael ^a   Laharie, David ^b   Cosnes, Jacques ^c   Allez, Matthieu ^d   Nancey, Stéphane ^e   Amiot, Aurélien ^f   Aubourg, Alexandre ^g   Fumery, Mathurin ^h   Altwegg, Romain ⁱ   Michetti, Pierre ^j   Chanteloup, Elise ^k   Seksik, Philippe ^c   Baudry, Clotilde ^d   Flamant, Mathurin ^l   Bouguen, Guillaume ^m   Stefanescu, Carmen ⁿ   Bourrier, Anne ^c   Bommelaer, Gilles ^o   Dib, Nina ^p   Bigard, Marc André ^q   Viennot, Stephanie ^r   Hébuterne, Xavier ^s   Gornet, Jean Marc ^d   Marteau, Philippe ^c   Bouhnik, Yoram ⁿ   Abitbol, Vered ^t   Nahon, Stéphane ^a   more..

^a Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h AMIENS UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

^j Clinique La Source   (Switzerland)

^k SAINT JOSEPH HOSPITAL   (France)

^l NANTES UNIVERSITY HOSPITAL   (France)

^m PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁿ BEAUJON HOSPITAL   (France)

^o HÔTEL DIEU   (France)

^p ANGERS UNIVERSITY HOSPITAL   (France)

^q CHU NANCY BRABOIS   (France)

^r CHU CÔTE DE NACRE   (France)

^s CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^t Institut Cochin   (France)

more..

Author keywords

Anti TNF; Crohn's disease; Inflammatory bowel disease; Screening; Tuberculosis; Ulcerative colitis

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ANTIBODY; ADALIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERANCE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEART TAMPONADE; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; THERAPY EFFECT; TRAVEL; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; ADOLESCENT; COMPLICATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 85016205167     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw129     Document Type: Article

References (24)

1. Annese V, Dana D, Corinne GR, Tine J, Ebbe L. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis 2016;10:216-25
2. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9
3. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-68
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
5. The French National Authority for Health 2006. Test de détection de la production d'IFNγ (interféron gamma) pour le diagnostic des infections tuberculeuses http://www.has-sante.fr/portail/jcms/r_1498744/fr/test-dedetection-de-la-production-d-ifng-interferon-gamma-pour-le-diagnosticdes-infections-tuberculeuses. Accessed December 13, 2006
6. Jauregui-Amezaga A, Turon F, Ordás I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013;7:208-12
7. Hofland RW, Thijsen SF, Verhagen MA, Schenk Y, Bossink AW. Tuberculosis during TNF-α inhibitor therapy, despite screening. Thorax 2013;68:1079-80
8. Debeuckelaere C, De Munter P, Van Bleyenbergh P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 2014;8:550-7
9. Cosnes J, Seksik P. Computer database for patients with IBD. In: Bayless TM, Hanauer SB, editors. Advanced Therapy in Inflammatory Bowel Disease. 3rd edn, vol. 1. Shelton, CT, USA: People's Medical Publishing House, 2011: 117-24
10. The French National Authority for Health 2007. Tuberculose active: http://www.has-sante.fr/portail/jcms/c_482999/en/active-tuberculosis. Accessed February 5, 2007
11. Shahidi N, Fu YT, Qian H, Bressler B. Performance of Interferon-gamma Release Assay in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:2034-42
12. The French National Authority for Health 2011. Vaccin BCG. http:// www.has-sante.fr/portail/jcms/c_1106827/en/vaccin-bcg. Accessed May 11, 2011
13. Institut de Veille Sanitaire 2010. http://www.invs.sante.fr/ display/?doc=publications/2010/vaccinations_BCG_enfants/index.html. Accessed February 19, 2010
14. Belard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-49
15. Wong SH, Ip M, Tang W, et al. Performance of Interferon-gamma Release Assay for tuberculosis screening in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2067-72
16. Wolf WA, Cotton CC, Runge T. Immunosuppression increases the odds of an indeterminate tuberculosis screen. Gastroenterology 2015;148:S-473
17. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783-90
18. Getahun H, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;373:1179-80
19. Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486-492
20. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52
21. Abreu C, Sarmento A, Magro F. Reintroduction of anti-TNF therapy after (or even during) anti-TNF associated tuberculosis in immune-mediated disease. J Crohns Colitis 2016;10:120-1
22. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21
23. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
24. Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol 2014;24:508-9